key: cord-1050818-5zjey3s0
authors: Stolp, Bettina; Stern, Marcel; Ambiel, Ina; Hofmann, Katharina; Morath, Katharina; Gallucci, Lara; Cortese, Mirko; Bartenschlager, Ralf; Ruggieri, Alessia; Graw, Frederik; Rudelius, Martina; Keppler, Oliver Till; Fackler, Oliver Till
title: SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models
date: 2022-01-28
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110387
sha: 38f631d944aebe4583a619d96a0943f0aed89933
doc_id: 1050818
cord_uid: 5zjey3s0

SARS-CoV-2 variants of concern (VOCs) display enhanced transmissibility and resistance to antibody neutralization. Comparing the early 2020 isolate EU-1 to the VOCs Alpha, Beta and Gamma in mice transgenic for human ACE2 reveals that VOCs induce a broadened scope of symptoms, expand systemic infection to the gastrointestinal tract, elicit depletion of natural killer cells and trigger variant-specific cytokine production patterns. Gamma infections result in accelerated disease progression associated with increased immune activation and inflammation. All four SARS-CoV-2 variants induce pDC depletion in lungs, paralleled by reduced interferon responses. Remarkably, VOCs also use the murine ACE2 receptor for infection to replicate in lungs of wildtype animals, which induce cellular and innate immune responses that apparently curtailed spread and overt disease. VOCs thus display distinct intrinsic pathogenic properties with broadened tissue and host range. Enhanced pathogenicity of VOCs and their potential for reverse zoonotic transmission poses challenges to clinical and pandemic management.

cytokine responses were also induced by EU-1 in the apparent absence of virus replication. 270

The emergence of SARS-CoV-2 VOCs has been recognized as a significant complication for 272 combatting the pandemic as they often display an increased capacity for transmission, higher 273 virulence and immune escape (Boehm et Gamma relative to the early SARS-CoV-2 isolate EU-1. Using identical amounts of infectious 276 virus for intranasal challenge of mice, we found that all variants induced rapid weight loss in 277

hACE2 Tg mice associated with increasing lethargy and respiratory distress. These disease 278 symptoms coincided with productive infection of the lung, trachea and brain and were 279 associated with immune activation and recruitment of inflammatory myeloid cells to the lung 280 as well as the marked production of pro-inflammatory, T cell-and myeloid cell-produced 281 cytokines and chemokines. However, VOCs displayed variant-specific characteristics that 282 include differences in disease progression, symptoms, tissue tropism, induction of cellular 283 immune activation and cytokine responses. These differences were particularly pronounced for 284

Gamma, which replicated to higher titers in the lung and led to significantly accelerated disease 285 progression. This increased virulence was paralleled by a more pronounced induction of 286 inflammatory monocytes and DCs as well as neutrophil recruitment to infected lungs. Possibly 287 reflecting this accelerated replication kinetics, cytokine responses of Gamma-infected animals 288 tended to be more pronounced early post infection, but showed reduced magnitude at the late 289 stage relative to that of animals infected with the other variants. Gamma thus represents the 290 prototype of a variant with significantly enhanced pathogenic potential in an in vivo model of 291 pathogenic infection. Together, these results reveal that SARS-CoV-2 VOCs bear different 292 intrinsic pathogenic potential and establish hACE2 Tg mice as a readily accessible disease 293 model for the characterization of newly emerging variants of this pandemic respiratory 294

Interestingly, we also noted that infection of the lung with all SARS-CoV-2 variants 296 tested resulted in a drastic reduction of pDCs numbers, one of the main producer cell types of 297 IFNs in this tissue. Consistently, lungs from infected animals showed a marked reduction of 298 IFN-α4, -β and -λ expression and both parameters were correlated (pDC depletion vs IFNß 299 protein p=0.0014; pDC depletion vs IFN mRNA p=0.0022). This phenotype was absent in 300 tissues not supporting robust virus replication (data not shown) and no correlation was observed 301 between pDC depletion and production of IFN, which is predominantly produced by 302 lymphocytes. Interestingly, pDCs are not productively infected ex vivo, but activated upon 303 SARS-CoV-2 exposure (Onodi et al., 2021) . Our in vivo study demonstrates that SARS-CoV-304 2 replication in lung tissue results in depletion of this cell type critical for immunosurveillance 305 and early innate responses. Since pDC depletion was most pronounced in the context of active 306 virus replication but still triggered with reduced efficacy by the replication-incompetent EU-1 307 inoculum in WT mice, the extent of pDC depletion is likely a function of local virus load. In 308 particular in case of VOCs, reduction of NK cell numbers, which was positively correlated with 309 of IFN responses that are likely to limit virus spread (data not shown). VOCs may thus just "not 338 yet" have optimized their replication and immune evasion strategies to these additional tissues. 339 A surprising and important observation was that all VOCs, but not EU-1, were able to 340 replicate in WT mice that only express murine ACE2. This could reflect that the spike proteins 341 of Alpha, Beta and Gamma have a 27-to 108-fold increased affinity for mouse ACE2 over that 342 of early SARS-CoV-2 variants enabling cell entry . However, infections of 343 WT mice were generally asymptomatic and limited to the lung, where new infectious progeny 344 was produced to markedly lower levels than in hACE2 Tg mice (up to 1600-fold less viral 345 genome copies and 22-fold less infectious viral progeny). The magnitude of affinity increase 346 for mouse ACE2 and VOC's replication capacity in WT mice were not correlated with another, 347

suggesting that in addition to the spike protein, additional viral determinants may contribute to 348 the ability of VOCs to replicate in WT mice. In comparison to EU-1, Alpha, Beta and Gamma 349 display 24, 29 and 25 mutations throughout the genome, 11, 10 and 13 within spike, 350 respectively (Table S1 ). Most strikingly, a three amino acid deletion in the non-structural 351 protein Nsp6 (∆106-108) is shared by all VOCs and may contribute to the observed replication 352 capacity in WT mice e.g. by its ability to promote evasion from type I IFN and its potential role Table S1 ). Future studies will assess the impact of these 362 mutations on SARS-CoV-2 replication and pathogenesis. Similarly, pDC depletion, immune 363 cell recruitment, suppression of IFN expression, and induction of cytokine production was 364 observed, but less pronounced than in Tg mice. Together, our results suggest that VOCs gained 365 the ability to infect lungs of WT mice and that initial triggering of immune responses allowed 366 the animals to systemically control these infections. Importantly, such rapid basal immune 367 responses were triggered by all variants analyzed including EU-1. Since EU-1 failed to replicate 368 in WT mice, these responses were likely elicited by the virus inoculum without the need for Analysis of additional organs is shown in Figure S8 . Mutations in the different SARS-CoV-2 504 variants that may account for the observed differences are summarized in Table S1 . Table S1 . LGL GISAID EPI ISL: 2095177 Chemicals, peptides, and recombinant proteins Antibiotic/Antimycotic (100x) Gibco, ThermoFisher Scientific 10 -2 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 10 6 10 7 S sgmRNA expression (rel. to GAPDH) 10 -2 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 10 6 10 7 S sgmRNA expression (rel. to GAPDH) 10 -2 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 10 6 10 7 S sgmRNA expression (rel. to GAPDH) viral gene expression 3 dpi 5/6 dpi 3 dpi 5/6 dpi 3 dpi 5/6 dpi 3 dpi 5/6 dpi J o u r n a l P r e -p r o o f Stolp et al. show that infection of transgenic mice with early SARS-CoV-2 variant EU-1 or variants of concern (VOCs) Alpha, Beta and Gamma result in lethal infection with strainspecific patterns of immune cell recruitment, cytokine production and organ tropism. Gamma displays enhanced pathogenicity. VOCs replicate in lungs of wildtype mice.

SARS-CoV-2 genomic and subgenomic 749

RNAs in diagnostic samples are not an indicator of active replication

Sources of Type I 751

Interferons in Infectious Immunity: Plasmacytoid Dendritic Cells Not Always in the Driver's Seat

Neutralization of SARS-CoV-2 variants by convalescent 755 and BNT162b2 vaccinated serum

Novel SARS-CoV-2 757 variants: the pandemics within the pandemic

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

A mouse-adapted model of SARS-CoV-2 to 763 test COVID-19 countermeasures

Evolution of antibody immunity to SARS-CoV-2. 766

Multiple SARS-CoV-2 variants escape 769 neutralization by vaccine-induced humoral immunity

Type I interferon production by plasmacytoid 771 dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct 772 cytokines

Human angiotensin-converting enzyme 2 transgenic mice 775 infected with SARS-CoV-2 develop severe and fatal respiratory disease

Emerging SARS-CoV-2 Variants and Impact in 777

Global Vaccination Programs against SARS-CoV-2/COVID-19

IFN-α production by plasmacytoid dendritic cells stimulated with RNA-780 containing immune complexes is promoted by NK cells via MIP-1β and LFA-1

SARS-CoV-2 variants, spike mutations and 784 immune escape

SARS-CoV-2 Cell Entry Depends on ACE2 and 787 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 D614G variant exhibits efficient replication 790 ex vivo and transmission in vivo

ACE2 mouse models: a toolbox for cardiovascular and 792 pulmonary research

Innate immune sensing of coronavirus and viral 794 evasion strategies

SARS-CoV-2 structure and replication 797 characterized by in situ cryo-electron tomography

Tracking Changes in SARS-CoV-2 Spike: Evidence that 800 D614G Increases Infectivity of the COVID-19 Virus

Early IFN-α signatures and 803 persistent dysfunction are distinguishing features of NK cells in severe COVID-19

CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Severe and persistent depletion of circulating plasmacytoid 809 dendritic cells in patients with 2009 pandemic H1N1 infection

COVID-19 preclinical models: human angiotensin-811 converting enzyme 2 transgenic mice

Functional landscape of SARS-CoV-2 cellular restriction

Multicentre comparison of 817 quantitative PCR-based assays to detect SARS-CoV-2

Lethality of SARS-CoV-2 infection in K18 821 human angiotensin-converting enzyme 2 transgenic mice

SARS-CoV-2 Causes a Different Cytokine Response Compared to Other 824

Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients

SARS-CoV-2 induces human plasmacytoid predendritic cell 827 diversification via UNC93B and IRAK4

SARS-CoV-2 one year on: 829 evidence for ongoing viral adaptation

Cytokines and Chemokines in SARS-CoV-831 2 Infections-Therapeutic Strategies Targeting Cytokine Storm

The role 833 of autophagy in controlling SARS-CoV-2 infection: An overview on virophagy-mediated molecular 834 drug targets

The multifaceted biology of plasmacytoid dendritic cells

Covid-19: Perspectives on Innate 838

Improvements to the ARTIC multiplex PCR method for SARS-841

CoV-2 genome sequencing using nanopore. bioRxiv

Coronavirus biology and 843 replication: implications for SARS-CoV-2

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to 846 use ACE2 receptors from additional species

Prospective Longitudinal Serosurvey of Health Care 849 Workers in the First Wave of the SARS-CoV-2 Pandemic in a Quaternary Care Hospital in Munich

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe 853 lung inflammation and impaired function

SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked 856 ubiquitination of NEMO

Evasion of Type I Interferon by SARS-CoV-2

K18-hACE2 mice develop respiratory 861 disease resembling severe COVID-19

The ORF8 protein of SARS-CoV-2 mediates immune evasion through

COVID-19 treatments and 867 pathogenesis including anosmia in K18-hACE2 mice

SARS-CoV-2 spike D614G change enhances replication and 870 transmission

Increased sCD163 and sCD14 Plasmatic Levels and 873

Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells 874 in Patients With Severe COVID-19 Pneumonia

synthesis was performed for 60min at 37°C, 5min at 95°C on a PCR cycler. Detection of SARS-663CoV-2 N1 gene (Taqman). Real-time RT-PCR (genomic) was performed using SARS-CoV-2 664 N1 gene primers (500nM) and probe (125nM) in a standard Taqman PCR in a QuantStudio 3 665Real-Time PCR System. Dilution series of the N positive control reference standard plasmid 666 were prepared in nuclease-free water. Slope of the curve was calculated by performing a linear 667 regression. Detection of Interferons and housekeeping genes (SYBR Green): RT-qPCR was 668 performed using either indicated IFNs or GAPDH forward and reverse primers (600nM each). 669Quantification of ISGs and GAPDH was done in a standard PowerUp SYBR Green PCR master 670 mix on a QuantStudio 3 Real-Time PCR System. Detection of SARS-CoV-2 sgmRNAs. RT-671 qPCR was performed using either SARS-CoV-2 forward primer leader universal (600nM) in 672 combination with a gene-specific sgmRNA reverse primer (600nM). Quantification of 673 sgmRNAs was done in a standard PowerUp SYBR Green PCR on a QuantStudio 3 Real-Time 674 PCR System. 675 676 Plaque assay. Plaque assays were essentially performed as previously described (Klein et al., 677 2020) . Briefly, Vero E6 cells were seeded into 24-well plates at 2.5x10 5 cells/well. Next day, 678 six times ten-fold serial dilutions of infectious supernatants or cleared organ homogenates were 679 prepared in complete DMEM, medium was removed from the plates and 200µL were added to 680 the cells in duplicates. Infection was performed at 37°C for 1 to 3hrs, followed by removal of 681 supernatant and overlaying with 1mL of minimum essential medium (MEM) containing 0.8% 682 Carboxymethylcellulose and incubation for 72hrs at 37°C. For testing of ileum, colon or feces 683 homogenates 1:100 antibiotic/antimycotic solutions was added at any step. Cells were then 684 fixed by overlay with 1mL 10% PBS-buffered formaldehyde for at least 30min at room 685 temperature, followed by immersion of the whole plates in 6% H2O-diluted formaldehyde for 686 at least 30min at room temperature before they were taken out of the BSL3 area. Water-rinsed 687 cell monolayers were stained for 15 to 30min with 2.3% crystal violet solution, extensively 688